REG - Hemogenyx Pharma Plc - Placing to Raise £451,250 and Director’s Dealing

Hemogenyx PharmaceuticalsAnnouncement

08/05/2025 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH7761Ha&default-theme=true

RNS Number : 7761H  Hemogenyx Pharmaceuticals PLC  08 May 2025

8 May 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Hemogenyx Secures £451,250 to continue its Phase 1 Clinical Trials

And

Director's Dealing

Introduction

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
raised gross proceeds of £451,250 (before expenses) via an allotment to
Vladislav Sandler of 250,000 new ordinary shares of £0.01 each ("New Ordinary
Shares") at an issue price of 180.5p (being the bid price as at close of
business on 7 May 2025) (the "Issue Price").

The net proceeds of this fundraise will be dedicated to the continuation of
the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell
therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid
leukemia in adults ("R/R AML"). As shareholders will be aware, the first two
patients have now been infused with HG-CT-1.

Issuance of the New Ordinary Shares

The Company is currently unable to issue and admit the New Ordinary Shares
without either the publication of an FCA approved prospectus or relying upon
an exemption to the requirement to issue a prospectus.

 

Consequentially, this fundraise involves the acceptance by Vladislav Sandler,
CEO and director of the Company to subscribe for the New Ordinary Shares at
the Issue Price pursuant to the employee offer exemption under Article 1(4)(i)
and 1(5) (h) of the UK Prospectus Regulation.

Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed
to direct their issue to an institution, who will immediately sell these New
Ordinary Shares at the same Issue Price to a purchaser identified by it (the
"Purchaser").

Warrants

Concurrent with the purchase of the New Ordinary Shares, the Purchaser will
receive warrants from the Company on a one-for-one basis. These warrants will
be exercisable for a period of 36 months at an exercise price of 270 pence
("Exercise Price"), subject to adjustment in certain circumstances as set out
in the warrant instrument including a reset of the Exercise Price if the
Company completes a share issuance (or other transaction granting rights to
subscribe for equity securities) during the Exercise Period at a price lower
than the Exercise Price.

Total Voting Rights

Application will be made for the 250,000 New Ordinary Shares, which will
rank pari passu in all respects with the existing Ordinary Shares of the
Company, to be admitted to the FCA official list and to trading on the equity
shares (transition) category of the Official List maintained by the FCA and to
trading on the main market for listed securities of the LSE, which is expected
to occur on or around 8.00 a.m. on 14 May 2025 ("Admission").

Upon Admission, the total number of issued shares and the total number of
voting rights in the Company will be 4,343,539.

The above figure of 4,343,539 should be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

The Company will keep the market informed of future developments as trials
proceed.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"We are pleased to have secured this funding from a single, committed investor
on terms that reflect confidence in the long-term value of Hemogenyx. The fact
that the raise was completed at the market price, with no discount, sends a
clear signal: this investor sees meaningful upside in our share price as we
advance HG-CT-1 through clinical development. Their support allows us to
maintain momentum in our Phase I trial without diluting value unnecessarily."

UK Market Abuse Regulation (UK MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

Director's Dealing Notification

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Vladislav Sandler
 2.  Reason for the Notification
 a)  Position/status                                              PDMR

 b)  Initial notification / Amendment                             Initial notification

 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Hemogenyx Pharmaceuticals plc

 b)  LEI                                                          2138008L93GYU5GN6179

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary Shares of £0.01
     Identification Code                                          GB00BQVXM815

 b)  Nature of the transaction                                    Off Market Allotment

 c)  Price(s) and volume(s)                                       Price(s)                          Volume(s)

                                                                  180.5  pence per Ordinary Share   250,000 Ordinary Shares
 d)  Aggregated information:

     Aggregated volume                                            250,000 Ordinary Shares

     Price                                                        180.5 pence per Ordinary Share

 e)  Date of the transaction                                      7 May 2025

 f)  Place of the transaction                                     London

d)

Aggregated information:

Aggregated volume

Price

 

250,000 Ordinary Shares

180.5 pence per Ordinary Share

 

 

e)

Date of the transaction

7 May 2025

 

f)

Place of the transaction

London

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEUPUQPAUPAGMM